Nabumétone Tillomed (Nabumetone)

Nabumetone is a pro‑drug that is metabolized to an active compound which reversibly blocks cyclooxygenase‑1 and cyclooxygenase‑2 enzymes. By inhibiting these enzymes, it lowers prostaglandin production, which are chemicals that drive inflammation, pain, and fever.

The specific dose of Nabumétone Tillomed is determined by the prescribing clinician based on the patient’s condition, severity, age, renal and hepatic function, and other individual factors. Patients should follow the dosage instructions provided by their healthcare professional.

Safety data for nabumetone in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nabumetone is a non‑acetylated NSAID that may have a slightly lower risk of gastrointestinal irritation compared with some traditional NSAIDs, but it shares similar cardiovascular and renal safety considerations. Choice of NSAID should be individualized based on patient risk factors and therapeutic response.

Nabumétone Tillomed should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight, and sources of heat to maintain its stability and potency.

The medication is taken orally, usually with a full glass of water. It can be taken with or without food, but taking it with food may reduce occasional stomach discomfort.

Serious risks include gastrointestinal bleeding or ulceration, severe liver injury, acute kidney failure, and rare but life‑threatening skin reactions such as Stevens‑Johnson syndrome. Patients should be monitored for signs of these events and seek immediate medical attention if they occur.

Patients with a known hypersensitivity to nabumetone or other NSAIDs, active peptic ulcer disease, severe heart failure, uncontrolled hypertension, or significant renal or hepatic impairment should avoid using this medication unless specifically directed by a physician.